NanoMosaic secured an FDA Advanced Manufacturing Technology (AMT) designation for its Nanoneedle/Tessie platform, marking regulatory recognition of a high‑throughput QC assay for AAV gene therapy manufacturing. The designation is intended to accelerate regulatory engagement and prioritized interactions for developers using the platform to measure vector genome integrity and capsid titers. NanoMosaic and industry statements emphasize the technology’s ability to provide multiplexed, molecular‑level critical quality attributes—data regulators and manufacturers view as pivotal for scaling AAV potency and consistency.